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Introduction: Increased levels of circulating von Willebrand Factor (VWF) in its active, platelet-binding confor-
mation have been implicated in the pathogenesis of several thrombotic conditions as well as bleeding conditions
characterized by severe thrombocytopenia. However, it is unclear whether the proportion of activated VWF in the
circulation also plays a role in patients with mild to moderate bleeding without thrombocytopenia.
Methods: Citrated plasma samples were collected from 145 patients with a bleeding diathesis with unknown cause.
Active VWF levels were measured with an in-house developed ELISA assay. In addition, VWF antigen (VWF:Ag),
VWF ristocetin cofactor activity (VWF:RCo) and (flow-cytometric) platelet-VWF binding (Plt:VWF) were
determined.
Results: Active VWF levels were on average mildly, but not significantly, lowered in patients with a bleeding
diathesis compared to the reference interval (especially in individuals with non-O blood groups). Active VWF was
not significantly different for subjects with (median 107.4%, IQR 18.3) versus without (median 111.1%, IQR
32.3%) an increased bleeding score, nor between subjects with suspected VWD (median 104%, IQR 20.6%) versus
other suspected causes of bleeding diathesis (median 111.7%, IQR 33.3%).
Conclusion: In this clinically heterogeneous population of patients with a mild bleeding phenotype, quantification
of active VWF levels does not have added diagnostic value to VWF:Ag and VWF activity assays in the diagnosis of
unexplained bleeding disorders.Dear Editors,
Whereas the diagnosis of established bleeding disorders, such as
haemophilia, is well defined, there are many patients with a mild to
moderate bleeding diathesis (e.g. frequent epistaxis, menorrhagia, pro-
longed post-operative bleeding) of unknown cause, who pose a signifi-
cant diagnostic challenge [1]. Following initial screening based on
personal/family history, bleeding scores, full blood cell count and routine
coagulation screening tests (e.g. PT and aPTT), these patients can be
referred for further evaluation of clotting factor activity, platelet function
testing (e.g. PFA-200®, light transmission aggregometry (LTA)) and von
Willebrand factor (VWF) antigen/activity [2]. The diagnosis of von
Willebrand Disease (VWD) is based on VWF antigen concentration
(VWF:Ag) and VWF function tests, most commonly the VWF ristocetin
cofactor activity (VWF:RCo) [3]. However, VWF:RCo assays suffer fromte, Pastoor Habetsstraat 50, 621
uskens).
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evier Ltd. This is an open accesshigh variability and may give falsely low VWF activities as a result of
polymorphisms. A more recently developed assay uses recombinant GPIb
fragments with two gain-of-function mutations that allow binding to
VWF (VWF:GPIbM) [3]. Although this assay does not require ristocetin
like the VWF:RCo assay, it is based on non-physiological binding of VWF
to a mutant receptor.
Recently, we developed an immunosorbent assay, based on a variable
heavy chain antibody fragment (VHH), to quantify active VWF. This is
the haemostatically active fraction of VWF that is circulating in vivo in its
platelet GP1bα-binding conformation. In a healthy study population,
only a small proportion of VWF was in its active conformation [4].
Several pathological conditions have been associated with increased
levels of active VWF, using an assay based on the same VHH for active
VWF [5]. The spontaneous interaction between active VWF and platelets
can tilt the haemostatic balance to either the prothrombotic (e.g. TTP and7 KM, Maastricht, the Netherlands.
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increased active VWF levels compared to healthy controls, respec-
tively) or the bleeding (e.g. von Willebrand disease (VWD) type 2B) side
[5]. In VWD type 2B, enhanced binding of platelets to active VWF (2–15
fold increased levels compared to healthy controls [5], due to
gain-of-function mutations in the A1 domain) results in clearance of
high-molecular-weight (HMW) VWF multimers and platelets, and
consequently a bleeding phenotype.
However, it is unclear whether the proportion of activated VWF in the
circulation also plays a role in patients with mild to moderate bleeding
without thrombocytopenia. It can be hypothesized that, since individuals
with relatively high circulating active VWF levels are more at risk for
spontaneous platelet-aggregate formation, relatively low circulating
active VWF levels may delay clot formation and hence contribute to a
mild bleeding diathesis. Therefore, we investigated whether in a popu-
lation of patients with a mild bleeding diathesis there were more patients
with very low active VWF levels compared to a control population. In
addition, we sought to identify cases in which active VWF levels may
have additional diagnostic value over the commonly used VWF:Ag and
VWF:RCo assays.
Between December 2014 and December 2017, patients with a mild
bleeding diathesis of unknown cause were recruited for participation in
the current study in the Ghent University Hospital in Belgium. All pa-
tients were referred by their haematologist for laboratory evaluation for
diagnosis of a bleeding disorder. The types of bleeding seen in these
patients were frequent hematomas (n ¼ 23), epistaxis (n ¼ 19), menor-
rhagia (n ¼ 6), petechiae/ecchymoses (n ¼ 9), heavy postpartum
bleeding (n ¼ 6), prolonged post-surgical bleeding (n ¼ 10), gingival
bleeding (n ¼ 4) and combinations of these bleeding symptoms. For 13
patients there was a clinical suspicion of von Willebrand’s disease (as
depicted in Fig. 2B). The study was approved by the Ethical Committee of
the Ghent University Hospital. Citrated whole blood was collected by
antecubital venipuncture (BD Vacutainer, Becton Dickinson, Plymouth,
UK). Platelet-poor plasma (PPP) was prepared and subsequently stored at
80 C until further testing. Active VWF was quantified using an ELISA,Fig. 1. VWF parameters in patients with a bleeding diathesis compared to refere
classification are depicted as red dots, those with a non-significant bleeding score as
dots. Reference ranges are depicted as dashed lines. For VWF:Ag and VWF:RCo, soli
blood group O. For Plt:VWF binding with high ristocetin the reference interval wa
ristocetin only the upper limit is depicted as a dashed line, the lower limit is not releva
MFI values of an unstimulated (no ristocetin) control condition. The horizontal bars
score. Abbreviations: NPP, normal pooled plasma; VWF:Ag, VWF antigen; VWF:RCo
tocetin. (For interpretation of the references to colour in this figure legend, the read
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based on a variable heavy chain antibody (VHH) specific for VWF in its
GP1bα-binding conformation, as described previously [4]. Normal
pooled plasma (NPP) was used as a standard in every plate and sample
results were normalized (%) to NPP on the same plate. VWF antigen
(VWF:Ag) and VWF:RCo were measured using the HemosIL® AcuStar
VWF:Ag assay and the HemosIL® AcuStar VWF:RCo assay, respectively
(IL-Werfen, Bedford, MA, USA). Platelet-VWF binding (Plt:VWF) was
measured by flow cytometry, as described previously [4], and is
expressed as median fluorescence intensity (MFI), corrected for the MFI
of the control condition without ristocetin. The ISTH-BAT bleeding
scores were determined by consulting the medical records, by one and
the same person (clinical pathologist) to avoid bias, and were considered
elevated if> 5 in women,>3 in men and>2 in children [6]. Associations
between continuous variables were determined using the non-parametric
Spearman’s rank correlation coefficient. Differences in active VWF levels
between two groups were compared using the non-parametric Man-
n-Whitney U test. Comparison of active VWF levels between three groups
was performed using the non-parametric Kruskal-Wallis test. A p-value of
0.05 was considered statistically significant for all comparisons.
We included 145 patients (32 men, 89 women, 24 children) with a
bleeding diathesis of unknown cause. The ISTH-BAT bleeding score was
documented for 109 subjects (24 men, 68 women, 17 children), and was
increased above the respective reference ranges [6] for 10 men, 12
women and 7 of the included children.
Active VWF levels in the entire study population (n ¼ 145) correlated
significantly with all other VWF parameters (except Plt:VWF binding
with low ristocetin), with almost identical correlation coefficients to
those previously found in a healthy population [4]. The strongest cor-
relation (Spearman’s r ¼ 0.442, p < 0.001) existed between active VWF
and VWF:Ag, followed by VWF:RCo (r ¼ 0.399, p < 0.001) and Plt-VWF
binding in the presence of a high (1.2 mg/mL) concentration of ristocetin
(r ¼ 0.386, p < 0.001).
In these subjects with a bleeding tendency, active VWF, VWF:Ag
levels and VWF:RCo activity were relatively lower, albeit not statistically
significant, compared to the previously determined reference intervalsnce values. Patients with a significant bleeding score according to the ISTH-BAT
blue dots and individuals with an unknown bleeding score are depicted as grey
d lines represent reference intervals for blood group non-O and dashed lines for
s previously determined in 56 healthy donors. For Plt:VWF binding with low
nt. For both Plt:VWF with low and high ristocetin, MFI values were corrected for
represent the medians, with the colour indicating the group based on bleeding
, VWF ristocetin cofactor activity; Plt:VWF, platelet to VWF binding; Risto, ris-
er is referred to the Web version of this article.)
Fig. 2. Active VWF related to clinically signifi-
cant bleeding and suspected VWD. (A) Active
VWF is not different in subjects with significant
bleeding (defined as >5 in women, >3 in men and
>2 in children) and (B) not different in subjects with
suspected von Willebrand disease versus other sus-
pected causes of the bleeding diathesis. The grey
area delineates the reference interval determined in
a previous study in healthy individuals [4]. Hori-
zontal bars represent the median. Abbreviations:
NPP, normal pooled plasma; VWD, von Willebrand
disease.
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(Fig. 1A–D). Several individuals had higher, but none had lower Plt:VWF
binding in response to ristocetin compared to the reference range in
healthy controls (Fig. 1E and F). Red dots indicate individuals with a
significant bleeding score. Active VWF was not significantly different for
subjects with versus without an increased bleeding score (Fig. 2A),
although it must be noted that the bleeding score does not always
correlate optimally with clinical bleeding tendency [8].
Active VWF was not significantly different between subjects with
suspected VWD versus other suspected causes of bleeding diathesis
(Fig. 2B). In VWD 2B patients, bleeding is due to thrombocytopenia as a
result of the clearance of platelet-VWF-aggregates. In the current study
31 patients had a platelet count below 150  109/L, of which three pa-
tients had a platelet count below 50  109/L. Only one of these three
thrombocytopenic patients had active VWF levels above the reference
range (209.2%), concurrently with mildly elevated VWF:Ag (241.6%)
and normal VWF:RCo activity (206.4%), hence this thrombocytopenia is
not due to VWD type 2B, but may rather be explained by a
thrombocytopathy.
In one patient with a bleeding diathesis, active VWF levels were
increased almost 5-fold (497%), in conjunction with substantially
increased VWF:Ag (323.5%) and mildly elevated VWF:RCo (234.3%) and
FVIII (200.0%) levels. The platelet count was normal (232  109/L).
However, light transmission aggregometry (LTA) demonstrated a platelet
ATP secretion defect and primary wave disaggregation upon stimulation
with epinephrine. A second patient with strongly elevated active VWF
levels (247.5%) had a similar pattern of increased VWF level and activity,
and was also suspected for a platelet secretion defect. Thus, the bleeding
symptoms in these patients can be explained by platelet secretion defects,
but the cause of the high (active) VWF levels and activity in these patients
remains unknown. However, since both were elderly patients (70 and 77
years) they may be (partly) attributed to comorbidities that affect
endothelial VWF secretion and activation, in particular inflammatory
conditions. Inflammation induces activation of the endothelium, result-
ing in excessive release of VWF into the circulation, whereas inflamma-
tion reduces the activity of the VWF-cleaving protease ADAMTS13, hence
active VWF levels increase [9]. Unfortunately, no inflammatory markers
(e.g. CRP) were measured to confirm this was the cause of the elevated
active VWF levels.
One patient with an active VWF level that was not above the reference
interval but relatively high (142%) compared to the low VWF:Ag (54.6%)
and VWF:RCo (50.8%) was diagnosed with Henoch-Schonlein purpura.
This is a rare inflammatory disease of the small blood vessels. The
presence of abnormally large (and hence active) multimers has previ-
ously been described for patients with this disease [10].
On the other end of the spectrum, three patients with a bleeding
tendency of unknown cause had active VWF levels below the lower limit3
of the reference interval (91.6%). All also had VWF:Ag (41.6–66.6%) and
VWF:RCo (41.2–57.9%) on the lower end of their reference intervals
with normal FVIII levels (69.1–86.2%) and platelet count (159–269 
109/L). Their bleeding symptoms were not more severe or distinct from
those of the patients with increased active VWF, hence the decreased
active VWF levels seem to have no clinical relevance in these patients.
In conclusion, in this highly heterogeneous population of individuals
with a bleeding diathesis, active VWF levels were on average slightly,
albeit not significantly, lower compared to healthy individuals. The
diagnosis of mild bleeding disorders is very challenging, and in approx-
imately half of the cases, the underlying cause is not found [1]. This study
adds that, in this population, quantification of active VWF levels does not
have added diagnostic value to VWF:Ag and VWF activity assays in the
diagnosis of unexplained bleeding disorders.
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